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Purpose: To evaluate the effect of pars plana vitrectomy (PPV) with internal limiting 
membrane (ILM) peeling for management of refractory diffuse diabetic macular 
edema (DME).
Methods: In this prospective interventional case series, eyes with refractory diffuse 
DME unresponsive to macular photocoagulation and/or intravitreal bevacizumab, and 
best corrected visual acuity (BCVA) ≥20/200 and ≤20/60 underwent triamcinolone-
assisted PPV with ILM peeling. Pre- and postoperative evaluations included a complete 
ophthalmologic examination, fluorescein angiography and optical coherence tomography 
(OCT). Main outcome measures were BCVA and central macular thickness (CMT).
Results: Twelve eyes of 12 patients with mean age of 59.6±3.9 (range, 55-68) years 
were operated and followed for a mean period of 4.9±1.0 (range, 4-6) months. Mean 
BCVA at final examination was 0.82 ± 0.18 logMAR which was not significantly better 
than its preoperative value of 1.00 ± 0.80 logMAR (P=0.959). Visual acuity improved 
by at least 2 lines in 3 eyes (25%), remained stable in 7 eyes (58%) and decreased 
by at least 2 lines in 2 eyes (17%). Mean CMT at final examination was 315±95 µm, 
which was significantly less than its preoperative value of 467±107 µm (P=0.004). 
Complications included vitreous hemorrhage in 2 and cataract progression in 5 eyes.
Conclusion: PPV with ILM peeling for refractory diffuse DME seems to reduce 
macular thickness, but does not significantly improve visual acuity as observed after 
an intermediate-term follow up of about 6 months.
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INTRODuCTION
Macular edema is the leading cause of visual 
impairment in patients with diabetes mellitus.1 
It progressively decreases visual acuity, with 
more than half of the patients losing at least 2 
lines within 2 years.2 Diffuse diabetic macular 
edema (DME) is caused by extensive breakdown 
of the inner and outer blood-retina barrier, 
and its treatment is more challenging than 
that of focal edema which usually responds 
to laser macular photocoagulation (MPC) of 
microaneurysms. Several studies have shown 
that diffuse DME entails poor visual prognosis 
despite MPC.3-6
It has been suggested that after spontaneous Vitrectomy with ILM Peeling for DME; Dehghan et al
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detachment or surgical removal of the posterior 
hyaloid, tangential traction exerted by residual 
cortical vitreous and the internal limiting 
membrane (ILM) plays an important role in 
DME. Therefore there has been interest in pars 
plana deep vitrectomy (PPV) combined with 
ILM removal.7 Recent studies have suggested 
that PPV with ILM removal is effective for 
reducing or resolving DME and improving 
visual acuity.7-14
The purpose of this prospective study 
was to evaluate the effectiveness and safety of 
triamcinolone-assisted PPV together with ILM 
peeling in diffuse refractory DME unresponsive 
to MPC or intravitreal bevacizumab (IVB).
METHODS
In this prospective interventional case series, 
consecutive eyes with diffuse DME refractory 
to MPC and/or IVB at Labbafinejad Medical 
Center, Tehran, Iran from September 2006 to 
September 2008 were evaluated for eligibility. 
Inclusion criteria were: 1- persistent diffuse DME 
defined as central macular thickness (CMT) 
≥250µm with history of at least two sessions 
of MPC or IVB, or one session of each modality 
performed more than 4 months prior to PPV; 
and 2- best corrected visual acuity (BCVA) 
≥20/200 and ≤20/60. Exclusion criteria were: 
1- lens opacity precluding optical coherence 
tomography (OCT); 2- massive hard exudates 
in the fovea; 3- very severe non-proliferative 
diabetic retinopathy (NPDR) or any degree of 
proliferative diabetic retinopathy (PDR); 4- 
previous vitreoretinal surgery; 5- evidence of 
posterior vitreous detachment (PVD) and/or 
vitreomacular traction; 6- angiographic evidence 
of macular ischemia; 7- any concomitant ocular 
disease; and 8- monocular patients.
Preoperative  evaluations  included 
determination of Snellen BCVA, biomicroscopic 
examination of the anterior and posterior 
segments, fluorescein angiography (FA), and 
OCT (3D OCT-1000, Topcon Corporation, Tokyo, 
Japan) for measuring CMT.
Written informed consent was obtained 
from those who fulfilled the study criteria 
before proceeding with surgery. All eyes 
underwent standard 20-gauge three-port PPV. 
After core vitrectomy, induction of PVD was 
initiated on the nasal side of the optic disc 
using aspiration from a soft-tipped cannula 
or vitrector. After completion of vitrectomy, 
0.1 ml (4 mg) of triamcinolone was injected 
over the macula with the infusion turned off 
and then washed out immediately with active 
suction. The ILM was incised with a bent MVR 
blade and peeled at a distance of at least one 
disc diameter from the fovea in all directions 
using intraocular forceps. No tamponade was 
used at the end of surgery.
Postoperatively, all patients were visited one 
day, one and four weeks after the procedure, and 
every 2 to 3 months thereafter. Chloramphenicol, 
betamethasone, and cycloplegic drops were 
started postoperatively and gradually tapered 
off within 4 weeks. At each follow up visit, 
Snellen BCVA was determined and a complete 
ophthalmologic examination was performed; 
OCT and FA were repeated every 3 months.
Cataract surgery was performed whenever 
the lens opacity was severe enough to preclude 
FA and/or OCT. Pre- and postoperative BCVA 
was converted to logarithm of minimum 
angle of resolution (logMAR) notations and 
compared by Wilcoxon signed-rank test. Pre- 
and postoperative CMT were also compared 
by Wilcoxon signed-rank test.
RESuLTS
Twelve eyes of 12 patients (6 male) were 
included in the study. Table 1 shows basic 
characteristics, and pre- and post-operative 
BCVA and CMT. Mean age of the patients 
was 59.6±3.9 (range, 55-68) years and all 
subjects had type 2 diabetes mellitus. Diabetic 
retinopathy was graded as severe NPDR in 6 
eyes and as moderate NPDR in 6 other eyes. 
In all eyes, macular edema was appreciated 
biomicroscopically, and diffuse fluorescein 
leakage was visible angiographically. All eyes 
had received at least two sessions of MPC, and/
or IVB. The mean intervals between the most 
recent MPC or IVB, and PPV were 7.1 (range, 
5-14) and 5 (range, 4-9) months, respectively.
Mean BCVA at final follow-up was 0.82±0.18 Vitrectomy with ILM Peeling for DME; Dehghan et al
164 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2010; Vol. 5, No. 3
logMAR which was not significantly better than 
its preoperative value of 1.00±0.80 logMAR 
(P=0.959). Visual acuity improved by at least 
2 lines in 3 eyes (25%), remained stable in 7 
eyes (58%) and decreased by at least 2 lines 
in 2 eyes (17%).
Mean CMT at final follow-up was 315±95 
µm, which was significantly less than its 
preoperative value of 467±107 µm (Wilcoxon 
test, P=0.004). At final examination, CMT had 
decreased by more than 20% in 6 of 12 eyes 
(50%).
No major intraoperative complication 
developed in any of the patients. Two eyes 
developed PDR with vitreous hemorrhage 
(cases 1 and 3) during the follow-up period 
and required repeat deep vitrectomy. Case 3 
developed neovascular glaucoma with poorly 
controlled intraocular pressure (IOP); this 
subject underwent cyclophotocoagulation 
and IOP was eventually controlled without 
any medications. Preoperatively, one eye was 
pseudophakic (case 2) while the others had 
mild or no lens opacity. After vitrectomy, 
progression of lens opacity occurred in 5 eyes, 
but no eye required cataract surgery up to 6 
months of follow up. After 6 months, cases 1 
and 3 underwent cataract surgery. Table 2 shows 
mean pre- and postoperative BCVA and CMT 
after excluding cases 1 and 3 who developed 
vitreous hemorrhage.
DISCuSSION
DME remains a significant cause of visual 
impairment in developed countries. The 
cornerstone for treatment of DME is MPC, 
which has been shown to reduce the incidence 
of moderate visual loss in eyes with clinically 
significant macular edema by 50%.2 In eyes 
with diffuse DME, however, the visual response 
to MPC is less encouraging.15 Lee and Olk6 
in their series of 302 eyes with diffuse DME 
treated by MPC, reported visual improvement 
equivalent to three Early Treatment of Diabetic 
Retinopathy Study (ETDRS) chart lines or 
more in only 13.7% of eyes at one year, and 
visual decline in 25% after three years. Visual 
CMT (μm) BCVA (logMAR)
F/u (Months) Grade of NPDR Eye Sex Age (years) Case
Final Baseline Final Baseline
- 503 HM 20/200 6 Severe OS M 62 1
248 276 20/160 20/120 6 Severe OS M 60 2
392 455 HM 20/120 6 Severe OD M 60 3
409 564 20/160 20/200 6 Moderate OS F 68 4
276 554 20/25 20/200 4 Moderate OS F 65 5
252 591 20/60 20/60 4 Severe OD F 55 6
215 341 20/100 20/160 4 Severe OD M 60 7
228 623 20/320 20/200 4 Moderate OD F 62 8
359 420 20/80 20/80 4 Moderate OS M 58 9
467 452 20/200 20/160 4 Severe OS F 60 10
409 485 20/50 20/80 5 Moderate OD M 58 11
191 357 20/100 20/120 6 Moderate OD F 55 12
Table 1. Demographic information, preoperative and postoperative visual acuity and central macular thickness in eyes 
with refractory diffuse diabetic macular edema
NPDR, non-proliferative diabetic retinopathy; F/U, follow-up; BCVA, best corrected visual acuity; CMT, central macular thickness; 
M, male; F, female; OS, left eye; OD, right eye; HM, hand motions
Preoperative Postoperative
Mean change P value
Mean±SD Range Mean±SD Range
BCVA (logMAR) 0.80±0.19 0.48-1 0.68±0.31 0.0-1.1 0.13±0.30 P=0.159
CMT (µm) 468±107 276-623 307±97 191-467 159±135 P=0.007
SD, standard deviation; BCVA, best corrected visual acuity; CMT, central macular thickness
Table 2. Pre- and postoperative mean BCVA and CMT excluding cases 1 and 3 who developed postoperative vitreous 
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rehabilitation for this subset of patients, who do 
not respond to laser photocoagulation, presents a 
significant challenge. The biological plausibility 
of vitrectomy for DME has been suggested by 
clinical observations that PVD is associated with 
a lower incidence of DME. In a retrospective 
study by Nasrallah et al16 only 20% of eyes with 
DME had PVD, whereas 55% of eyes without 
DME had PVD. Vitrectomy has been shown to 
be efficacious in eyes with identifiable hyaloid 
thickening or contraction, but results in eyes 
without hyaloidal abnormalities are conflicting.
In this prospective interventional case 
series of patients with refractory diffuse DME 
treated by PPV combined with ILM peeling, we 
observed a significant improvement in foveal 
thickness. However, visual acuity improvement 
was not significant, even after excluding 2 
eyes complicated by postoperative vitreous 
hemorrhage. Visual acuity improvement by 
two or more lines has been reported in 43 
to 92% of eyes undergoing PPV with ILM 
removal.7-11,17 There are reports that PPV with 
ILM peeling reduces retinal thickness without 
improvement in vision.18-20 In our study, the 
percentage of eyes that experienced at least 
2 lines of improvement (25%), was less than 
that of the above-mentioned studies7-11,17. Such 
discrepancies may be due to differences in: 1- 
duration of macular edema prior to surgery; 
2- prior MPC and/or IVB; 3- severity of diabetic 
retinopathy; 4- severity of macular ischemia 
which cannot always be detected on FA; and 
5- duration of follow up.
There is agreement in nearly all previous 
studies that PPV with ILM peeling significantly 
reduces macular thickness,7-12,14 although this 
is not exactly correlated with improvement 
in visual acuity,18-20 as has been the case in 
our study. The disparity between anatomic 
and visual outcomes may be due to both an 
increase in lens opacity and worsening of 
diabetic retinopathy.
The role of ILM removal in DME is unclear. 
Some investigators have reported PPV without 
ILM removal to be as effective as surgery 
with ILM removal in terms of reduction in 
retinal thickness and improvement in visual 
acuity.12,21 Conversely, a retrospective study 
reported that PPV effectively reduced DME, but 
results were better in eyes with ILM removal 
than those without ILM removal.17 Gandorfer 
et al7 observed that diffuse macular edema 
which progresses despite PPV together with 
posterior hyaloid and epiretinal membrane 
removal for non-clearing vitreous hemorrhage, 
resolves rapidly after ILM removal. Kimura 
et al14 also described prompt resolution of 
diabetic cystoid macular edema in eyes that had 
undergone previous PPV without an epiretinal 
membrane. Residual cortical vitreous has been 
demonstrated to remain attached to the macula 
after removal of the posterior hyaloid during 
triamcinolone-assisted PPV.22 Internal limiting 
membrane thickening and cell abundance on 
the vitreous side of the ILM has been observed 
in eyes with diabetic maculopathy.23 Therefore, 
ILM peeling may have a beneficial effect in DME 
by removing the tangential traction exerted 
by the ILM and residual cortical vitreous. 
Furthermore, ILM removal may also have a 
beneficial effect in preventing postoperative 
epiretinal membrane formation by removing 
the scaffold for proliferating cells. Postoperative 
epiretinal membrane formation, which has been 
described in 10.2% to 13.8% of eyes after PPV 
without ILM peeling,24-26 was not observed in 
our study and other similar studies utilizing 
PPV with ILM peeling,7-12 except for one study 
which reported epiretinal membrane formation 
in 5% of eyes.14
Postoperative complications in our study 
included progression of diabetic retinopathy 
from NPDR to PDR with vitreous hemorrhage 
in 2 eyes and neovascular glaucoma in one 
other eye; the latter complication may not have 
been related to deep vitrectomy. Progression 
in lens opacity which occurred in 5 eyes is a 
common finding after vitrectomy.
Of the limitations of the current study 
is the possible edema-reducing effect of 
vitrectomy, removal of the posterior hyaloids, 
and triamcinolone. During the procedures, 
we attempted to completely wash out the 
injected triamcinolone, so that its effect would 
be negligible. Moreover, systemic factors, 
especially HbA1c and lipid levels, may have 
acted as confounding factors but were not Vitrectomy with ILM Peeling for DME; Dehghan et al
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evaluated in our study.
In conclusion, vitrectomy with ILM peeling 
for refractory diffuse DME may reduce macular 
thickness, but does not seem to significantly 
improve visual acuity during intermediate-term 
follow up of about 6 months. A large multicenter 
randomized controlled trial comparing PPV 
with and without ILM peeling with longer 
follow up is required to establish the role of 
ILM removal for treatment of DME.
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